



This report is prepared for the Warsaw Stock Exchange SA within the framework of the Analytical Coverage Support Program 3.0.

Daily 19.IX.2022

Company	LT fundamental recommendation	12M EFV (PLN)	ST market-relative bias	Analyst
<b>BioMaxima</b>	<b>Not rated</b>	37.1	<b>Not rated</b>	Sylvia Jaśkiewicz, CFA Mikołaj Stępień, Michał Zameł

**Event: Buyback update**

The Company informed that between September 12 and 16 it had purchased 7 950 shares (0.1837% of the share capital) and a number of own shares obtained in the pending buyback reached 171,200 (4.0% of the share capital).

**Expected impact:** *Neutral.*

---

*The report is not a recommendation within the meaning of Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest.*